Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
June 11, 2025
Telix Pharmaceuticals Limited announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix (kit for the preparation of gallium-68 gozetotide injection), is now commercially available